Vaccination strategies for Parkinson disease: Induction of a swift attack or raising tolerance?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 852-867

  Romero Ramos, Marina ^a   Chelpin, Marianne Von Euler ^a   Sanchez Guajardo, Vanesa ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Antibodies; Cytokines; Dopamine; Humoral response; Immunomodulation; T cells; Tolerance; Treg

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN MONOCLONAL ANTIBODY; AMANTADINE; BCG VACCINE; BEE VENOM; DOPAMINE; FREUND ADJUVANT; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEVODOPA; MONOCLONAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; RANTES; RECOMBINANT ALPHA SYNUCLEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOLOGIC FACTOR;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIBODY TITER; APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOPAMINERGIC NERVE CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; MICROGLIA; MPTP-INDUCED PARKINSONISM; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REVIEW; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; DISEASE MODEL; IMMUNE SYSTEM; IMMUNOLOGY; MONONUCLEAR CELL; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); VACCINATION;

ALPHA-SYNUCLEIN; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; PARKINSON DISEASE; VACCINATION;

EID: 84899890502     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28578     Document Type: Review

References (198)

1. Martí MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003; 18(Suppl 6):S21-7; PMID:14502652; http://dx.doi.org/10.1002/mds.10559
2. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009; 24(Suppl 2):S656-64; PMID:19877243; http://dx.doi.org/10.1002/mds.22672
3. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55:174-9; PMID:14755720; http://dx.doi.org/10.1002/ana.10846
4. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-8; PMID:9462735; http://dx.doi.org/10.1038/ng0298-106
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7; PMID:9197268; http://dx.doi.org/10.1126/science.276.5321.2045
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302:841; PMID:14593171; http://dx.doi.org/10.1126/science.1090278
7. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164-73; PMID:14755719; http://dx.doi.org/10.1002/ana.10795
8. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998; 55:151-2; PMID:9482355; http://dx.doi.org/10.1001/archneur.55.2.151
9. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28:7687-98; PMID:18650345; http://dx.doi.org/10.1523/JNEUROSCI.0143-07.2008
10. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005; 280:22670-8; PMID:15840579; http://dx.doi.org/10.1074/jbc. M501508200
11. Lee JT, Wheeler TC, Li L, Chin LS. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum Mol Genet 2008; 17:906-17; PMID:18065497; http://dx.doi.org/10.1093/hmg/ddm363
12. Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 2008; 118:3087-97; PMID:18704197; http://dx.doi.org/10.1172/JCI35781
13. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949-53; PMID:23161999; http://dx.doi.org/10.1126/science.1227157
14. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209:975-86; PMID:22508839; http://dx.doi.org/10.1084/jem.20112457
15. Bae EJ, Ho DH, Park E, Jung JW, Cho K, Hong JH, Lee HJ, Kim KP, Lee SJ. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein. Antioxid Redox Signal 2013; 18:770-83; PMID:22867050; http://dx.doi.org/10.1089/ars.2011.4429
16. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72:57-71; PMID:21982369; http://dx.doi.org/10.1016/j.neuron.2011.08.033
17. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211; PMID:12498954; http://dx.doi.org/10.1016/S0197-4580(02) 00065-9
18. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998; 95:6469-73; PMID:9600990; http://dx.doi.org/10.1073/pnas.95.11.6469
19. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013; 5:113-39; PMID:23506036; http://dx.doi.org/10.1042/AN20120066
20. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal 2009; 11:2151-66; PMID:19243239; http://dx.doi.org/10.1089/ars.2009.2460
21. Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther 2013; 138:311-22; PMID:23384597; http://dx.doi.org/10.1016/j.pharmthera.2013.01.013
22. Hutter-Saunders JA, Mosley RL, Gendelman HE. Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother 2011; 11:1703-15; PMID:22091596; http://dx.doi.org/10.1586/ern.11.163
23. Chu K, Zhou X, Luo BY. Cytokine gene polymorphisms and Parkinson's disease: a meta-analysis. Can J Neurol Sci 2012; 39:58-64; PMID:22384497
24. Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000; 58:143-51; PMID:11128604
25. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172:151-4; PMID:8084523; http://dx.doi.org/10.1016/0304-3940(94)90684-X
26. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-91; PMID:3399080; http://dx.doi.org/10. 1212/WNL.38.8.1285
27. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208:1-25; PMID:17720159; http://dx.doi.org/10.1016/j.expneurol.2007.07.004
28. Myers CL, Wertheimer SJ, Schembri-King J, Parks T, Wallace RW. Induction of ICAM-1 by TNFalpha, IL-1 beta, and LPS in human endothelial cells after downregulation of PKC. Am J Physiol 1992; 263:C767-72; PMID:1357985
29. Mbow ML, Rutti B, Brossard M. Infiltration of CD4+ CD8+ T cells, and expression of ICAM-1, Ia antigens, IL-1 alpha and TNF-alpha in the skin lesion of BALB/c mice undergoing repeated infestations with nymphal Ixodes ricinus ticks. Immunology 1994; 82:596-602; PMID:7835923
30. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009; 216:122-5; PMID:19732964; http://dx.doi.org/10. 1016/j.jneuroim.2009.08.001
31. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008; 5:45; PMID:18925972; http://dx.doi.org/10.1186/1742-2094-5-45
32. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 2009; 14:1082- 8; PMID:19837186; http://dx.doi.org/10.1016/j.drudis.2009.10.002
33. Barnum CJ, Tansey MG. The duality of TNF signaling outcomes in the brain: potential mechanisms? Exp Neurol 2011; 229:198-200; PMID:21377463; http://dx.doi.org/10.1016/j.expneurol.2011.02.016
34. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010; 51:474-9; PMID:21051678
35. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One 2012; 7:e47387; PMID:23082161; http://dx.doi.org/ 10.1371/journal.pone.0047387
36. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, Shani Y, Schwartz M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci 2004; 24:6133-43; PMID:15240805; http://dx.doi.org/10.1523/JNEUROSCI.0600-04.2004
37. Boschetti G, Nancey S, Sardi F, Roblin X, Flourié B, Kaiserlian D. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17:160-70; PMID:20848510; http://dx.doi.org/10.1002/ibd.21308
38. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85; PMID:15280421; http://dx.doi.org/10.1084/jem.20040165
39. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Treviño I, Blesch A, Tansey MG. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 2011; 19:46-52; PMID:20959812; http://dx.doi.org/10.1038/mt.2010.217
40. McCoy MK, Ruhn KA, Martinez TN, McAlpine FE, Blesch A, Tansey MG. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 2008; 16:1572-9; PMID:18628756; http://dx.doi.org/10.1038/mt.2008.146
41. Katsarou Z, Bostantjopoulou S, Hatzizisi O, Giza E, Soler-Cardona A, Kyriazis G. [Immune factors or depression? Fatigue correlates in Parkinson's disease]. Rev Neurol 2007; 45:725-8; PMID:18075986
42. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211:13-6; PMID:8809836; http://dx.doi.org/10.1016/0304-3940(96)12706-3
43. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008; 441:158-62; PMID:18582534; http://dx.doi.org/10.1016/j.neulet.2008.06.040
44. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm 1996; 103:1077-81; PMID:9013395; http://dx.doi.org/10.1007/BF01291792
45. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202:17-20; PMID:8787820; http://dx.doi.org/10.1016/0304-3940(95)12192-7
46. Almeida AR, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002; 169:4850-60; PMID:12391195
47. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J Immunol 2006; 177:192-200; PMID:16785514
48. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005; 11:493-8; PMID:16154792; http://dx.doi.org/10.1016/j.parkreldis.2005.07.005
49. Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S, Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 2001; 113:146-52; PMID:11137586; http://dx.doi.org/10.1016/S0165-5728(00)00422-7
50. Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, Bocharov EV, Bocharova OR, Polyschuk VV, Sherstnev VV, Morozova-Roche LA. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol 2011; 233:221-7; PMID:21239064; http://dx.doi.org/10.1016/j.jneuroim.2010.12.001
51. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6:1219-27; PMID:16244650; http://dx.doi.org/10.1038/ ni1265
52. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007; 178:2018-27; PMID:17277105
53. Müller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998; 98:142-4; PMID:9724016; http: //dx.doi.org/10.1111/j.1600- 0404.1998.tb01736.x
54. Hofmann KW, Schuh AF, Saute J, Townsend R, Fricke D, Leke R, Souza DO, Portela LV, Chaves ML, Rieder CR. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res 2009; 34:1401-4; PMID:19214748; http://dx.doi.org/10.1007/s11064-009-9921-z
55. Selikhova MV, Kushlinskii NE, Lyubimova NV, Gusev EI. Impaired production of plasma interleukin-6 in patients with Parkinson's disease. Bull Exp Biol Med 2002; 133:81-3; PMID:12170314; http://dx.doi.org/10.1023/A:1015120930920
56. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010; 468:56-8; PMID:19857551; http://dx.doi.org/10.1016/j.neulet.2009.10.062
57. Zhou L, Littman DR. Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 2009; 21:146-52; PMID:19328669; http://dx.doi.org/10.1016/j.coi.2009.03.001
58. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand 2007; 116:374-9; PMID:17986095; http://dx.doi.org/10.1111/j.1600-0404.2007.00894.x
59. Shimoji M, Pagan F, Healton EB, Mocchetti I. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 2009; 16:318-28; PMID:19551455; http://dx.doi.org/10.1007/s12640-009-9076-3
60. Klüter H, Vieregge P, Stolze H, Kirchner H. Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J Neurol Sci 1995; 133:134-9; PMID:8583216; http://dx.doi.org/10.1016/0022-510X(95)00180-A
61. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 1999; 53:141-5; PMID:10349502; http://dx.doi.org/10.1016/S0753-3322(99)80079-1
62. Hasegawa Y, Inagaki T, Sawada M, Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol Scand 2000; 101:159-64; PMID:10705937; http://dx.doi.org/ 10.1034/j.1600-0404.2000.101003159.x
63. Wandinger KP, Hagenah JM, Klüter H, Rothermundt M, Peters M, Vieregge P. Effects of amantadine treatment on in vitro production of interleukin-2 in denovo patients with idiopathic Parkinson's disease. J Neuroimmunol 1999; 98:214-20; PMID:10430055; http://dx.doi.org/10.1016/S0165- 5728(99)00093-4
64. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009; 23:55-63; PMID:18678243; http://dx.doi.org/10.1016/j.bbi.2008.07.003
65. Pacheco R, Riquelme E, Kalergis AM. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Cent Nerv Syst Agents Med Chem 2010; 10:65-83; PMID:20236043; http://dx.doi.org/10. 2174/187152410790780154
66. Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol 2009; 216:8-19; PMID:19732962; http://dx.doi.org/10.1016/j.jneuroim.2009.07.018
67. Mignini F, Streccioni V, Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Auton Autacoid Pharmacol 2003; 23:1-25; PMID:14565534; http://dx.doi.org/10.1046/j.1474-8673.2003.00280.x
68. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001; 9:23-33; PMID:11435749; http://dx.doi.org/10.1159/ 000049004
69. Saha B, Mondal AC, Basu S, Dasgupta PS. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol 2001; 1:1363-74; PMID:11460316; http://dx.doi.org/10.1016/S1567-5769(01)00068-6
70. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol 2009; 21:645-54; PMID:19332443; http://dx.doi.org/10.1093/intimm/dxp033
71. Prado C, Contreras F, González H, Díaz P, Elgueta D, Barrientos M, Herrada AA, Lladser A, Bernales S, Pacheco R. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol 2012; 188:3062-70; PMID:22379034; http://dx.doi.org/10.4049/ jimmunol.1103096
72. Josefsson E, Bergquist J, Ekman R, Tarkowski A. Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 1996; 88:140-6; PMID:8707341; http://dx.doi.org/10.1046/j.1365-2567.1996.d01-653.x
73. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A 1994; 91:12912-6; PMID:7809145; http://dx.doi.org/10.1073/pnas.91.26.12912
74. Cosentino M, Zaffaroni M, Marino F, Bombelli R, Ferrari M, Rasini E, Lecchini S, Ghezzi A, Frigo G. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol 2002; 133:233-40; PMID:12446028; http://dx.doi.org/10.1016/S0165-5728(02)00372-7
75. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun 2010; 24:525-8; PMID:19896530; http://dx.doi.org/10.1016/j.bbi.2009.10.015
76. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008; 8:460-71; PMID:18579442; http://dx.doi.org/10.1016/j.coph.2008.05.001
77. Dethy S, Laute MA, Van Blercom N, Damhaut P, Goldman S, Hildebrand J. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients. Clin Chem 1997; 43:740-4; PMID:9166225
78. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, Tayebati SK. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 2001; 117:133-42; PMID:11431013; http://dx.doi.org/10.1016/S0165-5728(01)00317-4
79. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114:975-9; PMID:12457396; http://dx.doi.org/10.1002/ajmg.b.10948
80. Gordon J, Barnes NM. Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol 2003; 24:438-43; PMID:12909457; http://dx.doi.org/10. 1016/S1471-4906(03)00176-5
81. Carr L, Tucker A, Fernandez-Botran R. In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells. J Neuroimmunol 2003; 137:87-93; PMID:12667651; http://dx.doi.org/10.1016/S0165- 5728(03)00047-X
82. Carr L, Tucker A, Fernandez-Botran R. The enhancement of T cell proliferation by L-dopa is mediated peripherally and does not involve interleukin-2. J Neuroimmunol 2003; 142:166-9; PMID:14512176; http://dx.doi.org/10.1016/S0165-5728(03)00270-4
83. Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol 2001; 31:3504-12; PMID:11745370; http://dx.doi.org/10.1002/1521-4141(200112)31:12〈3504:: AIDIMMU3504〉3.0.CO;2-F
84. Tsao CW, Lin YS, Cheng JT. Effect of dopamine on immune cell proliferation in mice. Life Sci 1997; 61:361-71; PMID:9399637; http://dx.doi.org/10.1016/S0024-3205(97)00962-4
85. Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996; 46:791-5; PMID:8618685; http://dx.doi.org/10.1212/WNL.46.3.791
86. Alberio T, Pippione AC, Comi C, Olgiati S, Cecconi D, Zibetti M, Lopiano L, Fasano M. Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease. IUBMB Life 2012; 64:846-52; PMID:22815142; http://dx.doi.org/10.1002/iub.1073
87. González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, Pacheco R. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J Immunol 2013; 190:5048-56; PMID:23589621; http://dx.doi.org/10.4049/jimmunol.1203121
88. Chi DS, Gong L, Daigneault EA, Kostrzewa RM. Effects of MPTP and vitamin E treatments on immune function in mice. Int J Immunopharmacol 1992; 14:739-46; PMID:1512070; http://dx.doi.org/10.1016/0192-0561(92)90070-2
89. Renoux G, Bizière K, Renoux M, Steinberg R, Kan JP, Guillaumin JM. Sodium diethyldithiocarbamate protects against the MPTP-induced inhibition of immune responses in mice. Life Sci 1989; 44:771-7; PMID:2539542; http://dx.doi.org/10.1016/0024-3205(89)90374-3
90. Bieganowska K, Członkowska A, Bidziński A, Mierzewska H, Korlak J. Immunological changes in the MPTP-induced Parkinson's disease mouse model. J Neuroimmunol 1993; 42:33-7; PMID:8423206; http://dx.doi.org/10.1016/ 0165-5728(93)90209-H
91. Cosentino M, Rasini E, Colombo C, Marino F, Blandini F, Ferrari M, Samuele A, Lecchini S, Nappi G, Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic Biol Med 2004; 36:1233-40; PMID:15110388; http://dx.doi.org/10.1016/j.freeradbiomed.2004.02.065
92. Ferreira TB, Kasahara TM, Barros PO, Vieira MM, Bittencourt VC, Hygino J, Andrade RM, Linhares UC, Andrade AF, Bento CA. Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder. J Neuroimmunol 2011; 238:58-66; PMID:21872345; http://dx.doi.org/10.1016/j.jneuroim.2011.06.009
93. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F, Lecchini S. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007; 109:632-42; PMID:16985181; http://dx.doi.org/10.1182/blood-2006-01-028423
94. Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, et al. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy. Neuroimmunomodulation 2012; 19:283-92; PMID:22472872; http://dx.doi.org/10.1159/000336981
95. Cosentino M, Marino F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J Neuroimmune Pharmacol 2013; 8:163-79; PMID:23074017; http://dx.doi.org/10.1007/s11481-012-9410-z
96. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 2012; 7:927-38; PMID:23054369; http://dx.doi.org/10. 1007/s11481-012-9402-z
97. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182-92; PMID:19104149
98. Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol 2013; 72:624-45; PMID:23771222; http://dx.doi.org/10.1097/NEN.0b013e31829768d2
99. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010; 5:e8784; PMID:20098715; http://dx.doi.org/10.1371/journal.pone.0008784
100. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008; 67:1149-58; PMID:19018246; http://dx.doi.org/10.1097/NEN.0b013e31818e5e99
101. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184:2261-71; PMID:20118279; http://dx.doi.org/10.4049/jimmunol.0901852
102. Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Nitrated alpha-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009; 182:4137-49; PMID:19299711; http://dx.doi.org/10.4049/jimmunol.0803982
103. Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H. gamma delta+ T cells are increased in patients with Parkinson's disease. J Neurol Sci 1994; 121:39-45; PMID:8133310; http://dx.doi.org/10.1016/0022-510X(94)90154-6
104. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001; 58:1580-3; PMID:11594915; http://dx.doi.org/10.1001/archneur.58.10.1580
105. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, Ward C, Halliday GM. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 2012; 252:95-9; PMID:22910543; http://dx.doi.org/10.1016/j. jneuroim.2012.07.015
106. Fiszer U, Mix E, Fredrikson S, Kostulas V, Link H. Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand 1994; 90:160-6; PMID:7847055; http://dx.doi.org/10.1111/j.1600-0404.1994. tb02699.x
107. Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int 2012; 12:102-7; PMID:21929737; http://dx.doi.org/10.1111/ j.1447-0594.2011.00740.x
108. Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G, Zangaglia R, Pacchetti C, Cereda C, Cova E, et al. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. Neurobiol Aging 2011; 32:2142-51; PMID:20106550; http://dx.doi.org/10.1016/j. neurobiolaging.2010.01.004
109. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140:845-58; PMID:20303875; http://dx.doi.org/10.1016/j.cell.2010.02.021
110. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007; 188:117-27; PMID:17582512; http://dx.doi.org/10.1016/j.jneuroim.2007.05.011
111. Wang L, Xie Y, Zhu LJ, Chang TT, Mao YQ, Li J. An association between immunosenescence and CD4(+)CD25(+) regulatory T cells: a systematic review. Biomed Environ Sci 2010; 23:327-32; PMID:20934123; http://dx.doi.org/10.1016/ S0895-3988(10)60072-4
112. Huber H, Descossy P, van Brandwijk R, Knop J. Activation of murine epidermal TCR-gamma delta+ T cells by keratinocytes treated with contact sensitizers. J Immunol 1995; 155:2888-94; PMID:7673705
113. Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R, Ferrarese C. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 2006; 23:36-43; PMID:16563783; http://dx.doi.org/10.1016/j.nbd.2006.01.013
114. Prigione A, Isaias IU, Galbussera A, Brighina L, Begni B, Andreoni S, Pezzoli G, Antonini A, Ferrarese C. Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Parkinsonism Relat Disord 2009; 15:327-8; PMID:18640066; http://dx.doi.org/10.1016/j.parkreldis.2008.05.013
115. Battisti C, Formichi P, Radi E, Federico A. Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation. J Neurol Sci 2008; 267:120-4; PMID:18061619; http://dx.doi.org/10.1016/j.jns.2007.10.012
116. Calopa M, Bas J, Callén A, Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 2010; 38:1-7; PMID:20044003; http://dx.doi.org/10.1016/j.nbd.2009.12.017
117. Meredith EJ, Holder MJ, Rosén A, Lee AD, Dyer MJ, Barnes NM, Gordon J. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci U S A 2006; 103:13485-90; PMID:16938864; http://dx.doi.org/10.1073/pnas. 0605993103
118. van de Warrenburg BP, Church AJ, Martino D, Candler PM, Bhatia KP, Giovannoni G, Quinn NP. Antineuronal antibodies in Parkinson's disease. Mov Disord 2008; 23:958-63; PMID:18383532; http://dx.doi.org/10.1002/mds.21929
119. Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG. Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 2013; 8:e60726; PMID:23589757; http://dx.doi.org/10.1371/journal.pone.0060726
120. Benkler M, Agmon-Levin N, Hassin-Baer S, Cohen OS, Ortega-Hernandez OD, Levy A, Moscavitch SD, Szyper-Kravitz M, Damianovich M, Blank M, et al. Immunology, autoimmunity, and autoantibodies in Parkinson's disease. Clin Rev Allergy Immunol 2012; 42:164-71; PMID:21234712; http://dx.doi.org/10.1007/ s12016-010-8242-y
121. Nagele E, Han M, Demarshall C, Belinka B, Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2011; 6:e23112; PMID:21826230; http://dx.doi.org/10.1371/journal. pone.0023112
122. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005; 128:2665-74; PMID:16219675; http://dx.doi.org/10.1093/brain/awh625
123. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG. Brain-reactive auto-antibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of bloodbrain barrier breakdown. Brain Res 2010; 1345:221-32; PMID:20546711; http://dx.doi.org/10.1016/j. brainres.2010.05.038
124. Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, Klawans HL. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology 1991; 41(Suppl 2):53-8, discussion 59-60; PMID:2041594; http://dx.doi.org/10.1212/WNL.41.5- Suppl-2.53
125. Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Siklós L, Appel SH. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998; 55:1075-80; PMID:9708957; http://dx.doi.org/10.1001/archneur.55.8.1075
126. He Y, Le WD, Appel SH. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002; 176:322-7; PMID:12359173; http://dx.doi.org/10.1006/ exnr.2002.7946
127. Rowe DB, Le W, Smith RG, Appel SH. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 1998; 53:551-8; PMID:9726426; http://dx.doi.org/10.1002/(SICI)1097- 4547(19980901)53:5〈551::AID-JNR5〉3.0.CO;2-8
128. Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 2009; 217:297-301; PMID:19289120; http://dx.doi.org/10.1016/j.expneurol.2009.03.002
129. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011; 1812:239-45; PMID:20600871; http://dx.doi.org/10.1016/j.bbadis.2010.06.009
130. Berer K, Wekerle H, Krishnamoorthy G. B cells in spontaneous autoimmune diseases of the central nervous system. Mol Immunol 2011; 48:1332-7; PMID:21146219; http://dx.doi.org/10.1016/j.molimm.2010.10.025
131. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7:852-8; PMID:18703007; http://dx.doi.org/10.1016/S1474-4422(08)70192-3
132. Wilson HL. B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics 2012; 6:117-23; PMID:22690126
133. Fontoura P. Roles of B lymphocytes in multiple sclerosis: diversifying beyond the antibody response. Immunotherapy 2009; 1:181-5; PMID:20635939; http://dx.doi.org/10.2217/1750743X.1.2.181
134. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420-30; PMID:18802481
135. Begum-Haque S, Christy M, Ochoa-Reparaz J, Nowak EC, Mielcarz D, Haque A, Kasper LH. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011; 232:136-44; PMID:21111489; http://dx.doi.org/10.1016/j.jneuroim.2010.10.031
136. Ray A, Mann MK, Basu S, Dittel BN. A case for regulatory B cells in controlling the severity of auto-immune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol 2011; 230:1-9; PMID:21145597; http://dx.doi.org/10.1016/j.jneuroim.2010.10.037
137. 't Hart BA, Jagessar SA, Haanstra K, Verschoor E, Laman JD, Kap YS. The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis. Front Immunol 2013; 4:145; PMID:23781220
138. Anwar Jagessar S, Fagrouch Z, Heijmans N, Bauer J, Laman JD, Oh L, Migone T, Verschoor EJ, 't Hart BA. The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model. J Neuroimmune Pharmacol 2013; 8:727-38; PMID:23508625; http://dx.doi.org/10.1007/s11481-013- 9448-6
139. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209:1001-10; PMID:22547654; http://dx.doi.org/10.1084/jem.20111675
140. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007; 101:749-56; PMID:17448146; http://dx.doi.org/10.1111/j.1471-4159.2006.04365.x
141. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 2011; 26:171-9; PMID:21593566
142. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 2011; 6:e18513; PMID:21541339; http://dx.doi.org/10.1371/journal.pone.0018513
143. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, Reindl M, Oertel WH, Noelker C, Bacher M, et al. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 2013; 80:169-75; PMID:23255825; http://dx.doi.org/10.1212/WNL.0b013e31827b90d1
144. Morozov SG, Ivanova-Smolenskaia IA, Markova ED, Piradov MA, Poleshchuk VV, Labunskiǐ DA, Gnedenko BB. [Immunochemical correlates of the severity of Parkinson's disease]. Vopr Med Khim 1997; 43:34-8; PMID:9281224
145. Fiszer U, Fredrikson S, Członkowska A. Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease. J Neurol Sci 1996; 139:66-70; PMID:8836974; http://dx.doi.org/10.1016/0022-510X(96)00002-0
146. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32:13454-69; PMID:23015436; http://dx.doi.org/10.1523/JNEUROSCI.1292-12.2012
147. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000; 18:423-49; PMID:10837065; http://dx.doi.org/10.1146/annurev.immunol.18.1.423
148. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3:944-50; PMID:12244307; http://dx.doi.org/10.1038/ni833
149. Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderón Gómez E, Sweenie CH, Hao Y, Freitas AA, Steinhoff U, Anderton SM, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008; 180:4763-73; PMID:18354200
150. Wang R, Han G, Wang J, Song L, Chen G, Xu R, Yu M, Qian J, Shen B, Li Y. The role of STAT3 in anti-gen-IgG inducing regulatory CD4(+)Foxp3(+)T cells. Cell Immunol 2007; 246:103-9; PMID:17697673; http://dx.doi.org/10.1016/j. cellimm.2007.07.001
151. Cousens LP, Su Y, McClaine E, Li X, Terry F, Smith R, Lee J, Martin W, Scott DW, De Groot AS. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res. 2013; 2013:621693
152. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010; 22:761-7; PMID:21087847; http://dx.doi.org/10.1016/j.coi.2010.10. 009
153. Barr TA, Gray M, Gray D. B cells: programmers of CD4 T cell responses. Infect Disord Drug Targets 2012; 12:222-31; PMID:22394172; http://dx.doi.org/10. 2174/187152612800564446
154. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012; 12:623-35; PMID:22903150; http://dx.doi.org/10.1038/nri3265
155. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2:a009381; PMID:22315722; http://dx.doi.org/10.1101/cshperspect.a009381
156. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 2010; 31:7-17; PMID:19879804; http://dx.doi.org/10.1016/j.it.2009.09.003
157. Schwartz M, Kipnis J. Therapeutic T cell-based vaccination for neurodegenerative disorders: the role of CD4+CD25+ regulatory T cells. Ann N Y Acad Sci 2005; 1051:701-8; PMID:16127010; http://dx.doi.org/10.1196/annals.1361. 114
158. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46:857-68; PMID:15953415; http://dx.doi.org/10.1016/j.neuron.2005.05.010
159. Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012; 18(Suppl 1):S11-3; PMID:22166404; http://dx.doi.org/10.1016/S1353-8020(11)70006-2
160. Avidan H, Kipnis J, Butovsky O, Caspi RR, Schwartz M. Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. Eur J Immunol 2004; 34:3434-45; PMID:15549735; http://dx.doi.org/10.1002/eji.200424883
161. Laćan G, Dang H, Middleton B, Horwitz MA, Tian J, Melega WP, Kaufman DL. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson's disease. J Neurosci Res 2013; 91:1292-302; PMID:23907992; http://dx.doi.org/10.1002/jnr.23253
162. Armentero MT, Levandis G, Nappi G, Bazzini E, Blandini F. Peripheral inflammation and neuro-protection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol Dis 2006; 24:492-505; PMID:17023164; http://dx.doi.org/10. 1016/j.nbd.2006.08.016
163. Chung ES, Kim H, Lee G, Park S, Kim H, Bae H. Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells. Brain Behav Immun 2012; 26:1322-30; PMID:22974722; http://dx.doi.org/10.1016/j.bbi.2012.08.013
164. Shinoda M, Hudson JL, Strömberg I, Hoffer BJ, Moorhead JW, Olson L. Allogeneic grafts of fetal dopamine neurons: immunological reactions following active and adoptive immunizations. Brain Res 1995; 680:180-95; PMID:7663976; http://dx.doi.org/10.1016/0006-8993(95)00260-W
165. Laurie C, Reynolds A, Coskun O, Bowman E, Gendelman HE, Mosley RL. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroimmunol 2007; 183:60-8; PMID:17196666; http://dx.doi.org/10.1016/j. jneuroim.2006.11.009
166. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 2007; 82:1083-94; PMID:17675560; http://dx.doi.org/10. 1189/jlb.0507296
167. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6:e19338; PMID:21559417; http://dx.doi.org/10.1371/ journal.pone.0019338
168. Kurkowska-Jastrzebska I, Bałkowiec-Iskra E, Joniec I, Litwin T, Członkowski A, Członkowska A. Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease. Neuroscience 2005; 131:247-54; PMID:15680707; http://dx.doi.org/10.1016/j.neuroscience.2004.10.027
169. Yong J, Lacan G, Dang H, Hsieh T, Middleton B, Wasserfall C, Tian J, Melega WP, Kaufman DL. BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One 2011; 6:e16610; PMID:21304945; http://dx.doi.org/10.1371/journal.pone.0016610
170. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101:9435-40; PMID:15197276; http://dx.doi.org/10.1073/ pnas.0400569101
171. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, Cerny R, Gelman B, Thomas MP, Mosley RL, et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem 2008; 104:1504-25; PMID:18036154; http://dx.doi.org/10.1111/j.1471- 4159.2007.05087.x
172. Liu Y, Qiang M, Wei Y, He R. A novel molecular mechanism for nitrated alpha-synuclein-induced cell death. J Mol Cell Biol 2011; 3:239-49; PMID:21733982; http://dx.doi.org/10.1093/jmcb/mjr011
173. Yu Z, Xu X, Xiang Z, Zhou J, Zhang Z, Hu C, He C. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One 2010; 5:e9956; PMID:20386702; http://dx.doi.org/10.1371/ journal.pone.0009956
174. Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millett IS, Doniach S, Lyubchenko YL, Fink AL. Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res Mol Brain Res 2005; 134:84-102; PMID:15790533; http://dx.doi.org/10.1016/j.molbrainres.2004.11.014
175. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004; 279:47746-53; PMID:15364911; http://dx.doi.org/10.1074/jbc.M408906200
176. Yamin G, Uversky VN, Fink AL. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 2003; 542:147-52; PMID:12729915; http://dx.doi.org/10.1016/S0014-5793(03)00367-3
177. McCormack AL, Mak SK, Di Monte DA. Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis 2012; 3:e315; PMID:22647852; http://dx.doi.org/10.1038/cddis.2012.50
178. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, et al. Nitrated alphasynuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008; 3:e1376; PMID:18167537; http://dx.doi.org/10.1371/journal.pone. 0001376
179. Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M, Weiner H, Kuchroo V. Reciprocal depvelomental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature Letters 2006; 441:235-8; http://dx.doi.org/10.1038/nature04753
180. Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014; PMID:24525765; http://dx.doi.org/10.1007/s00401- 014-1256-4
181. Bhattacharya P, Gopisetty A, Ganesh BB, Sheng JR, Prabhakar BS. GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol 2011; 89:235-49; PMID:21048215; http://dx.doi.org/10.1189/jlb.0310154
182. Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phe-nyl-1, 2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol 2013; 265:1-10; PMID:24210793; http://dx.doi.org/10.1016/j.jneuroim.2013.10.009
183. Kim NK, Choi BH, Huang X, Snyder BJ, Bukhari S, Kong TH, Park H, Park HC, Park SR, Ha Y. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced murine Parkinson's disease model. Eur J Neurosci 2009; 29:891-900; PMID:19245369; http://dx.doi.org/10.1111/j.1460-9568.2009. 06653.x
184. St-Amour I, Bousquet M, Paré I, Drouin-Ouellet J, Cicchetti F, Bazin R, Calon F. Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation 2012; 9:234; PMID:23046563; http://dx.doi.org/10.1186/1742- 2094-9-234
185. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007; 178:3447-56; PMID:17339439
186. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165:208-10; PMID:8015728; http://dx.doi.org/10.1016/0304-3940(94)90746-3
187. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012; 60:762-6; PMID:22910321; http://dx.doi.org/10.1016/j.cyto.2012.07.030
188. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100:34-41; PMID:10416510; ht tp: //dx.doi.org/10.1111/j. 1600-0404.1999.tb00721.x
189. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009; 119:332-7; PMID:18976327; http://dx.doi.org/10.1111/j.1600-0404.2008.01103.x
190. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995; 193:129-32; PMID:7478158; http://dx.doi.org/10.1016/0304-3940(95)11686-Q
191. Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol 1996; 142:313-22; PMID:8934562; http://dx.doi.org/10.1006/exnr.1996.0200
192. Scalzo P, de Miranda AS, Guerra Amaral DC, de Carvalho Vilela M, Cardoso F, Teixeira AL. Serum levels of chemokines in Parkinson's disease. Neuroimmunomodulation 2011; 18:240-4; PMID:21430395; http://dx.doi.org/10.1159/ 000323779
193. Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, Caponnetto S, Bendtzen K, Zappia M, Nicoletti F. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine 2011; 55:165-7; PMID:21550814; http://dx.doi.org/10.1016/j.cyto.2011.03.027
194. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol 2005; 169:161-71; PMID:16150496; http://dx.doi.org/10.1016/j.jneuroim.2005.07.013
195. Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J Interferon Cytokine Res 2005; 25:395-406; PMID:16022584; http://dx.doi.org/10.1089/jir.2005.25.395
196. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, Dasgupta PS. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol 2003; 3:1019-26; PMID:12810359; http://dx.doi.org/10.1016/S1567-5769(03)00100-0
197. Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J 2004; 18:1600-2; PMID:15319371
198. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, Basu S. Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol 2006; 177:7525-9; PMID:17114421